دورية أكاديمية
Histopathological concordance between prostate biopsies and radical prostatectomy specimens-implications of transrectal and transperineal biopsy approaches.
| العنوان: | Histopathological concordance between prostate biopsies and radical prostatectomy specimens-implications of transrectal and transperineal biopsy approaches. |
|---|---|
| المؤلفون: | Hagens MJ; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. m.hagens@nki.nl.; Department of Urology, Amsterdam University Medical Centers location Boelelaan, Amsterdam, the Netherlands. m.hagens@nki.nl.; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands. m.hagens@nki.nl., Ribbert LLA; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Jager A; Department of Urology, Amsterdam University Medical Centers location Boelelaan, Amsterdam, the Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands., Veerman H; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Urology, Amsterdam University Medical Centers location Boelelaan, Amsterdam, the Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands., Barwari K; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands.; Department of Urology, Andros Clinics, Amsterdam, the Netherlands., Boodt B; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands.; Department of Urology, Flevoziekenhuis, Almere, the Netherlands., de Bruijn RE; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands.; Department of Urology, Ziekenhuis Amstelland, Amstelveen, the Netherlands., Claessen A; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands.; Department of Urology, Rode Kruis Ziekenhuis, Beverwijk, the Netherlands., Leter MR; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands.; Department of Urology, Dijklander Ziekenhuis, Hoorn, the Netherlands., van der Noort V; Department of Statistics, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Smeenge M; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands.; Department of Urology, St Jansdal Ziekenhuis, Harderwijk, the Netherlands., Roeleveld TA; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands.; Department of Urology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands., Rynja SP; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands.; Department of Urology, Spaarne Gasthuis, Hoofddorp, the Netherlands., Schaaf M; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands.; Department of Urology, BovenIJ Ziekenhuis, Amsterdam, the Netherlands., Weltings S; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands.; Department of Urology, Zaans Medisch Centrum, Zaandam, the Netherlands., Vis AN; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Urology, Amsterdam University Medical Centers location Boelelaan, Amsterdam, the Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands., Bekers E; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., van Leeuwen PJ; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Urology, Amsterdam University Medical Centers location Boelelaan, Amsterdam, the Netherlands., van der Poel HG; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Urology, Amsterdam University Medical Centers location Boelelaan, Amsterdam, the Netherlands.; Prostate Cancer Network the Netherlands, Amsterdam, the Netherlands. |
| المصدر: | Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2024 Jun; Vol. 27 (2), pp. 312-317. Date of Electronic Publication: 2023 Sep 02. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9815755 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5608 (Electronic) Linking ISSN: 13657852 NLM ISO Abbreviation: Prostate Cancer Prostatic Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2002->: London : Nature Publishing Group Original Publication: Houndmills, Basingstoke, UK : Stockton Press, c1997- |
| مواضيع طبية MeSH: | Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/surgery , Prostatectomy*/methods, Humans ; Male ; Middle Aged ; Aged ; Neoplasm Grading ; Prostate/pathology ; Prostate/surgery ; Biopsy/methods ; Perineum/surgery ; Perineum/pathology ; Rectum/surgery ; Rectum/pathology ; Magnetic Resonance Imaging/methods ; Image-Guided Biopsy/methods ; Retrospective Studies |
| مستخلص: | Background: This study aimed to evaluate the histopathological concordance rates between prostate biopsies and radical prostatectomy specimens according to the applied biopsy approach (transrectal or transperineal). Methods: We studied patients who had been newly diagnosed with clinically significant prostate cancer and who underwent a radical prostatectomy between 2018 and 2022. Patients were included if they underwent a prebiopsy magnetic resonance imaging and if they had not been previously treated for prostate cancer. Histopathological grading on prostate biopsies was compared with that on radical prostatectomy specimens. Univariable and multivariable logistic regression analyses were performed to assess the effect of the applied biopsy approach on histopathological concordance. Additional analyses were performed to assess the effect of the applied biopsy approach on American Urological Association risk group migration, defined as any change in risk group after radical prostatectomy. Results: In total, 1058 men were studied, of whom 49.3% (522/1058) and 50.7% (536/1058) underwent transrectal and transperineal prostate biopsies, respectively. Histopathological disconcordance was observed in 37.8% (400/1058) of men while American Urological Association risk group migration was observed in 30.2% (320/1058) of men. A transperineal biopsy approach was found to be independently associated with higher histopathological concordance rates (OR 1.33 [95% CI 1.01-1.75], p = 0.04) and less American Urological Association risk group migration (OR 0.70 [95% CI 0.52-0.93], p = 0.01). Conclusions: The use of a transperineal biopsy approach improved histopathological concordance rates compared to the use of a transrectal biopsy approach. A transperineal biopsy approach may provide more accurate risk stratification for clinical decision-making. Despite recent improvements, histopathologic concordance remains suboptimal and should be considered before initiating management. (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.) |
| References: | Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. Grading committee. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244–52. (PMID: 10.1097/PAS.000000000000053026492179) van Leenders GJLH, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. ISUP grading workshop panel members. The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020;44:e87–99. (PMID: 10.1097/PAS.0000000000001497324597167382533) Wenzel M, Würnschimmel C, Chierigo F, Mori K, Tian Z, Terrone C, et al. Pattern of Biopsy Gleason grade group 5 (4 + 5 vs 5 + 4 vs 5 + 5) predicts survival after radical prostatectomy or external beam radiation therapy. Eur Urol Focus. 2022;8:710–7. (PMID: 10.1016/j.euf.2021.04.01133933420) Wenzel M, Würnschimmel C, Chierigo F, Flammia RS, Tian Z, Shariat SF, et al. Nomogram predicting downgrading in national comprehensive cancer network high-risk prostate cancer patients treated with radical prostatectomy. Eur Urol Focus. 2022;8:1133–40. (PMID: 10.1016/j.euf.2021.07.00834334344) Corcoran NM, Hong MK, Casey RG, Hurtado-Coll A, Peters J, Harewood L, et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int. 2011;108:E202–10. (PMID: 10.1111/j.1464-410X.2011.10119.x21443656) Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115:2388–99. (PMID: 10.1002/cncr.2428319399748) Diamand R, Oderda M, Al Hajj Obeid W, Albisinni S, Van Velthoven R, Fasolis G, et al. A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy. World J Urol. 2019;37:2109–17. (PMID: 10.1007/s00345-019-02634-930652213) Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N. Engl J Med. 2020;382:917–28. (PMID: 10.1056/NEJMoa1910038321308147323919) Goel S, Shoag JE, Gross MD, Al Hussein Al Awamlh B, Robinson B, Khani F, et al. Concordance between biopsy and radical prostatectomy pathology in the era of targeted biopsy: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3:10–20. (PMID: 10.1016/j.euo.2019.08.00131492650) Miller J, Perumalla C, Heap G. Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg. 2005;75:48–50. (PMID: 10.1111/j.1445-2197.2005.03284.x15740517) Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012;61:1110–4. (PMID: 10.1016/j.eururo.2011.12.05822244150) Grummet JP, Weerakoon M, Huang S, Lawrentschuk N, Frydenberg M, Moon DA, et al. Sepsis and “superbugs”: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int. 2014;114:384–8. (PMID: 10.1111/bju.1253624612341) Zattoni F, Marra G, Kasivisvanathan V, Grummet J, Nandurkar R, Ploussard G, et al. The detection of prostate cancer with magnetic resonance imaging-targeted prostate biopsies is superior with the transperineal vs the transrectal approach. a European association of urology-young academic urologists prostate cancer working group multi-institutional study. J Urol. 2022;208:830–7. (PMID: 10.1097/JU.000000000000280236082555) Rai BP, Mayerhofer C, Somani BK, Kallidonis P, Nagele U, Tokas T. Magnetic resonance imaging/ultrasound fusion-guided transperineal versus magnetic resonance imaging/ultrasound fusion-guided transrectal prostate biopsy-a systematic review. Eur Urol Oncol. 2021;4:904–13. (PMID: 10.1016/j.euo.2020.12.01233478936) Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76:340–51. (PMID: 10.1016/j.eururo.2019.02.03330898406) de Rooij M, Israël B, Tummers M, Ahmed HU, Barrett T, Giganti F, et al. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training. Eur Radio. 2020;30:5404–16. (PMID: 10.1007/s00330-020-06929-z) Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, et al. The FUTURE trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies. Eur Urol. 2019;75:582–90. Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. part I: risk stratification, shared decision making, and care options. J Urol. 2018;199:683–90. (PMID: 10.1016/j.juro.2017.11.09529203269) Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol. 2012;61:1019–24. (PMID: 10.1016/j.eururo.2012.01.050223363804659370) Qu LG, Al-Shawi M, Howard T, Papa N, Poyet C, Kelly B, et al. Gleason grade accuracy of transperineal and transrectal prostate biopsies in MRI-naïve patients. Int Urol Nephrol. 2021;53:2445–52. (PMID: 10.1007/s11255-021-03007-134623591) Marra G, Eldred-Evans D, Challacombe B, Van Hemelrijck M, Polson A, Pomplun S, et al. Pathological concordance between prostate biopsies and radical prostatectomy using transperineal sector mapping biopsies: validation and comparison with transrectal biopsies. Urol Int. 2017;99:168–76. (PMID: 10.1159/00047149128768264) Evans SM, Patabendi Bandarage V, Kronborg C, Earnest A, Millar J, Clouston D. Gleason group concordance between biopsy and radical prostatectomy specimens: a cohort study from prostate cancer outcome registry - Victoria. Prostate Int. 2016;4:145–51. (PMID: 10.1016/j.prnil.2016.07.004279951145153432) Zattoni F, Marra G, Martini A, Kasivisvanathan V, Grummet J, Harkin T, et al. Is there an impact of transperineal vs. transrectal mri-targeted biopsy on the risk of upgrading in final pathology in prostate cancer patients undergoing radical prostatectomy? An EAU-YAU prostate cancer working group multi-institutional study. Eur Urol Focus. 2023;9:621–8. Mai Z, Zhou Z, Yan W, Xiao Y, Zhou Y, Liang Z, et al. The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens. BMC Cancer. 2018;18:1205. (PMID: 10.1186/s12885-018-5124-9305142436278093) Cowan T, Baker E, McCray G, Reeves F, Houlihan K, Johns-Putra L. Detection of clinically significant cancer in the anterior prostate by transperineal biopsy. BJU Int. 2020;126:33–7. (PMID: 10.1111/bju.1512432463977) Hagens MJ, Luining WI, Jager A, Donswijk ML, Cheung Z, Wondergem M, et al. The diagnostic value of PSMA PET/CT in men with newly diagnosed unfavorable intermediate-risk prostate cancer. J Nucl Med. 2023;64:1238–43. Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Tian Z, et al. Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. Prostate Int. 2022;10:21–7. (PMID: 10.1016/j.prnil.2022.01.004352619118866049) Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, et al. Downgrading from Biopsy grade group 4 prostate cancer in patients undergoing radical prostatectomy for high or very high risk prostate cancer. J Urol. 2020;204:748–53. (PMID: 10.1097/JU.000000000000107432259468) Bullock N, Simpkin A, Fowler S, Varma M, Kynaston H, Narahari K. Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry. BMC Urol. 2019;19:94. (PMID: 10.1186/s12894-019-0526-9316235956798468) Bulten W, Pinckaers H, van Boven H, Vink R, de Bel T, van Ginneken B, et al. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncol. 2020;21:233–41. (PMID: 10.1016/S1470-2045(19)30739-931926805) De Luca S, Fiori C, Bollito E, Garrou D, Aimar R, Cattaneo G, et al. Risk of Gleason Score 3 + 4 = 7 prostate cancer upgrading at radical prostatectomy is significantly reduced by targeted versus standard biopsy. Minerva Urol Nefrol. 2020;72:360–8. Mandel P, Wenzel M, Hoeh B, Welte MN, Preisser F, Inam T, et al. Immunohistochemistry for prostate Biopsy-impact on histological prostate cancer diagnoses and clinical decision making. Curr Oncol. 2021;28:2123–33. |
| تواريخ الأحداث: | Date Created: 20230902 Date Completed: 20240515 Latest Revision: 20240515 |
| رمز التحديث: | 20240516 |
| DOI: | 10.1038/s41391-023-00714-x |
| PMID: | 37660218 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1476-5608 |
|---|---|
| DOI: | 10.1038/s41391-023-00714-x |